Global E-Cigarette Liquid Market to Reach $37 Billion by 2028

Aug.23.2022
Global E-Cigarette Liquid Market to Reach $37 Billion by 2028
The global e-cigarette liquid market is projected to reach $3.7 billion by 2028, driven by increasing health awareness and demand for safer smoking alternatives.

Market.US has released a research report stating that the global e-cigarette e-liquid market was valued at $1.7 billion in 2020 and is expected to reach $3.7 billion by 2028. The market is projected to grow at a CAGR of 12.8% from 2021 to 2028.


An increasing number of people are turning to safer smoking alternatives as awareness regarding health issues continues to grow. Electronic cigarettes are known to contain lower levels of toxic substances, and offer various flavors such as tobacco, mint, fruit, and nut. This is expected to fuel the consumption of e-cigarette oil.


Electronic cigarettes, unlike traditional tobacco cigarettes, do not contain tobacco and do not produce tar or carbon monoxide. This makes them a safer alternative to smoking. As people become more aware of the harmful effects of smoking on their health, they are more likely to quit, leading to a positive impact on the global sales of electronic cigarettes. This is one of the many reasons why the electronic cigarette industry is thriving.


Global E-liquid Market: Driving Factors


Electronic cigarette liquid is often used as a substitute for traditional tobacco. E-cigarette liquid can be infused with many flavors, providing a fresh and enhanced taste.


Electronic cigarettes are different from traditional cigarettes in that they allow you to inhale fewer toxic substances, reducing the risk of lung disease. These factors are expected to drive growth in the global liquid market. The use of e-liquid in electronic cigarettes helps reduce environmental damage, which is why manufacturers are focusing on liquid e-cigarettes, which are becoming increasingly popular. Green e-cigarettes are an obvious trend, eliminating the environmental burden associated with handling large amounts of cigarette butts.


Furthermore, electronic cigarettes reduce the issue of deforestation and the environmental degradation caused by tobacco production. Compared to traditional smoking, electronic cigarettes provide many advantages to smokers, helping them to reduce their intake of tar and nicotine and leading many to partially or completely quit smoking. These health benefits are driving demand for liquid nicotine in the electronic cigarette market. However, government regulation of e-cigarettes as tobacco products may hinder the future growth of the global e-liquid market.


The main trend in the market: Nicotine salts.


E-cigarettes are considered safer because they do not burn tobacco or produce tar or carbon monoxide. As knowledge about e-cigarettes increases, sales have also been on the rise. This is one of the main factors driving the growth of the e-cigarette oil market. Health authorities and organizations around the world are taking measures to reduce tobacco use, including indoor smoking bans and high taxes. This has encouraged people to use e-cigarettes as a means to quit smoking and has driven market growth.


Leading manufacturers are utilizing social media to promote their products, providing customized flavors, and implementing innovative marketing strategies. Online distribution channels are also being used for e-cigarette accessories and kits. With both open and closed systems becoming increasingly popular, there is an expected increase in global demand. The research report addresses the following questions:


Who are the main players in the electronic e-liquid market? What are the main driving factors for the growth of the electronic e-liquid market? Based on what types of categories is the global electronic e-liquid market classified? What is the expected market size and growth rate of the electronic e-liquid market in the future? In 2021, which distribution channels dominate the electronic e-liquid industry? What criteria are used when selecting companies?


Click to view a sample research report.


Statement


This article is compiled from third-party information and is intended solely for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity and accuracy of the article's content. The compilation of this article is only intended for industry communication and research.


Due to the limitations of the translation ability, the translated article may not accurately reflect the original text. Please refer to the original text for accuracy.


2FIRSTS is fully aligned with the Chinese government on any domestic, Hong Kong-Macau-Taiwan-related, and foreign related statements and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands has agreed to acquire 100% of Swedish modern oral nicotine company Yoik Group AB for an initial SEK515 million, equivalent to about US$53.9 million, plus a deferred payment linked to performance over the next two years. Yoik owns nicotine pouch brand Helwit, which held about 3.4% of Sweden’s modern oral nicotine market over the past 12 months. Imperial says the acquisition will more than double its existing share of the Swedish market. Helwit is also sold elsewhere in the Nordics, through European online channels and in selected UK retail outlets.
Sep.08
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.
Regulations
Oct.10
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03